Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

ClinicalTrials.gov ID: NCT04523207

Public ClinicalTrials.gov record NCT04523207. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Open-label, Single-arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy (ADT) in Treatment-naïve Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Main Study: The purpose of main study is to assess if the combination of apalutamide and androgen deprivation therapy (ADT) in participants with high-risk localized prostate cancer improves the biochemical recurrence (BCR) free rate. Sub-study: The purpose of the sub-study is to assess if the co administration of apalutamide and relugolix is able to maintain castrate levels of testosterone.

Study identification

NCT ID
NCT04523207
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
108 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 19, 2020 (Actual)
Primary completion
Oct 23, 2023 (Actual)
Completion
Oct 25, 2023 (Actual)
Last update posted
Apr 21, 2026

2020 – 2023

United States locations

U.S. sites
32
U.S. states
23
U.S. cities
31
Facility City State ZIP Site status
Arizona Urology Specialists 1 Tucson Arizona 85704 —
Arizona Urology Specialists Tucson Arizona 85741 —
Arkansas Urology Little Rock Arkansas 72211 —
Skyline Urology Sherman Oaks California 91411 —
Genesis Research Torrance California 90505 —
The Urology Center of Colorado Denver Colorado 80211 —
Foothills Urology - Golden Off Lakewood Colorado 80228 —
Urological Research Network Hialeah Florida 33016 —
Idaho Urologic Institute Meridian Idaho 83642 —
First Urology, PSC Jeffersonville Indiana 47130 —
The Iowa Clinic West Des Moines Iowa 50266 —
Wichita Urology Group Wichita Kansas 67226 —
Ochsner LSU Health Shreveport - Regional Urology Shreveport Louisiana 71106 —
Michigan Institute of Urology, PC Troy Michigan 48084 —
Adult Pediatric Urology & Urogynecology, P.C Omaha Nebraska 68114 —
New Jersey Urology LLC Voorhees Township New Jersey 08043 —
Great Lakes Physician PC d/b/a Western New York Urology Associates Cheektowaga New York 14225 —
Associated Medical Professionals Syracuse New York 13210 —
Associated Urologists of North Carolina Raleigh North Carolina 27612 —
The Urology Group Cincinnati Ohio 45212 —
Oregon Urology Institute Springfield Oregon 97477 —
MidLantic Urology Bala-Cynwyd Pennsylvania 19004 —
Lancaster Urology Lancaster Pennsylvania 17604 —
Carolina Urologic Research Center Myrtle Beach South Carolina 29572 —
Lexington Urology West Columbia South Carolina 20169 —
Urology Associates Nashville Tennessee 37209 —
Urology Austin Austin Texas 78745 —
Houston Metro Urology Houston Texas 77027 —
Urology San Antonio Research San Antonio Texas 78229 —
Virginia Urology Richmond Virginia 23235 —
Urology Of Virginia, Pllc Virginia Beach Virginia 23462 —
Spokane Urology Spokane Washington 99202 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04523207, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 21, 2026 · Synced Oct 31, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04523207 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →